Danish Real Estate Stock News

GN Store Nord (CPSE:GN) shares have been reacting to the company’s full year 2025 earnings, in which both sales and net income were lower than the prior year. This has put renewed attention on the stock’s recent performance. See our latest analysis for GN Store Nord. The full year 2025 earnings release appears to have been a key catalyst for the share price, with the stock posting a 1 day share price return of 1.05% and a 7 day share price return of 1.45% after a softer 30 day share price...

Genmab (CPSE:GMAB) has wrapped up FY 2025 with fourth quarter revenue of US$1.1b and basic EPS of US$0.50, rounding out a trailing twelve month EPS of US$15.5 on revenue of US$3.7b. The company has seen quarterly revenue move from US$715 million in Q1 2025 to US$1.1b in Q4, alongside EPS ranging from US$3.06 in Q1 to US$6.51 in Q3 and US$0.50 in Q4. This sets up a results season where investors are likely to focus on how these shifts flow through to margins and the durability of its earnings...

Jyske Bank (CPSE:JYSK) has put a new DKK 3,000m share buyback on the table, paired with fresh full year 2025 results and 2026 earnings guidance, giving investors several moving parts to assess. See our latest analysis for Jyske Bank. At a share price of DKK960.5, Jyske Bank has a 90 day share price return of 25.23% and a 1 year total shareholder return of 83.35%, suggesting strong momentum that recent earnings, guidance and the new buyback are now feeding into. If this kind of rerating in...

FLSmidth (CPSE:FLS) has completed its divestment of the cement business, becoming a pure mining technology and services supplier. The company has announced a new share buyback program alongside this business reshaping. These updates mark a key turning point in the group’s focus and capital allocation priorities. For you as an investor, CPSE:FLS is now a focused mining equipment and services company rather than a mixed mining and cement group. That shift matters if you follow trends in...

Netcompany Group (CPSE:NETC) has launched a share buyback programme of up to DKK 750 million, targeting as many as 3,250,000 shares to adjust its capital structure and cover share-based incentive commitments. See our latest analysis for Netcompany Group. At a share price of DKK307.4, Netcompany Group has a 1 year total shareholder return of 6.96%, while the year to date share price return of 12.47% suggests momentum has softened in recent months despite the newly announced buyback...

NKT (CPSE:NKT) has drawn fresh attention after announcing an exclusive power cable partnership with German grid operator Mainova. The agreement runs to 2033 and supports Frankfurt’s long term electricity network upgrade and electrification needs. See our latest analysis for NKT. Alongside this Mainova deal and recent news such as the power purchase agreement with Uniper and the upcoming CFO change, NKT’s 1 year total shareholder return of 64.04% and 5 year total shareholder return of 264.59%...

Q1 earnings snapshot and why it matters for shareholders Coloplast (CPSE:COLO B) has just reported first quarter results, with sales of DKK 7,043 million, net income of DKK 1,397 million, and basic earnings per share of DKK 6.2 from continuing operations. See our latest analysis for Coloplast. At a share price of DKK485.0, Coloplast has seen a 30 day share price return of 10.65% decline and a year to date share price return of 9.58% decline, while the 1 year total shareholder return of 36.64%...

Event driven snapshot of Aktieselskabet Schouw Aktieselskabet Schouw (CPSE:SCHO) has caught investors' attention after recent price moves, with the share closing at 700.0 DKK and showing positive total returns over the past month and past 3 months. See our latest analysis for Aktieselskabet Schouw. While the latest share price of DKK700.0 comes after a quiet 1 week, the 30 day share price return of 5.1% sits alongside a 1 year total shareholder return of 23.0%, suggesting momentum has been...

European Commission approves a new 7.2 mg weekly maintenance dose of Wegovy for adults with obesity. The decision expands the dosing options available to patients who do not achieve sufficient weight loss on the previous maximum dose. The approval broadens Novo Nordisk's obesity treatment portfolio within the EU market. Novo Nordisk (CPSE:NOVO B) now has an extended Wegovy label in the EU, adding a higher 7.2 mg maintenance dose to address patients who need additional weight loss support...

Genmab A/S has released its full-year 2025 results, reporting revenue of US$3.72 billion versus US$3.12 billion in 2024 and net income of US$963 million, alongside 2026 guidance calling for higher revenue but a potentially lower operating profit range of US$0.9–1.4 billion. The earnings update also highlighted FDA approval of Abkinley in second-line follicular lymphoma and a broadened oncology pipeline, including new Phase 3 trials and assets gained through acquisitions, which together...

Ørsted A/S' ( CPH:ORSTED ) robust earnings report didn't manage to move the market for its stock. We did some digging...

Vestas Wind Systems (CPSE:VWS) is back in focus after a busy update, featuring fourth quarter and full year 2025 results, fresh 2026 earnings guidance, a completed buyback, a proposed dividend, and new project wins. See our latest analysis for Vestas Wind Systems. Despite the flurry of news around earnings, guidance, the buyback and a new wind project, the share price at DKK157.35 reflects mixed momentum, with a weak 1 month share price return of a 14.8% decline, contrasting with a 1 year...

H. Lundbeck (CPSE:HLUN B) is back in focus after reporting positive phase IIb data from the PROCEED trial of bocunebart, a potential migraine preventive therapy targeting patients with prior treatment failures. See our latest analysis for H. Lundbeck. The positive PROCEED data has come just days after Lundbeck reported full year 2025 results and proposed a higher dividend, and the stock has reacted with a 1 day share price return of 2.97% and 7 day share price return of 4.42%. That said, the...

If you are wondering whether Novo Nordisk shares still offer value at current levels, this article will walk through what the numbers are really saying about the stock. The share price closed at DKK 307.65, with returns of 1.1% decline over 7 days, 20.9% decline over 30 days, 6.8% decline year to date and 44.4% decline over 1 year, set against a 50.1% gain over 5 years. This may leave you questioning whether recent moves signal changing growth expectations or shifting risk...

As European markets experience volatility and investors weigh the impact of AI disruption, the pan-European STOXX Europe 600 Index managed a slight gain, reflecting a cautiously optimistic outlook amid broader economic growth in the eurozone. In such an environment, dividend stocks can offer stability and income potential, making them attractive options for those seeking to navigate uncertain market conditions while benefiting from consistent returns.

Methanex and Ørsted (CPSE:ORSTED) have launched the U.K.'s first commercially ready biomethanol bunkering service at the Port of Immingham, giving investors a fresh data point on the company’s role in low carbon shipping fuels. See our latest analysis for Ørsted. That biomethanol bunkering launch comes after Ørsted’s recent full year 2025 earnings and a board change in early February, and it lands during a period of renewed share price momentum. The shares have a 30 day share price return of...

Aktieselskabet Schouw & Co. (CPSE:SCHO) shareholders approved the release of BioMar as an Original Guarantor under the company’s bond terms. The decision removes BioMar from its status as a Material Subsidiary in the bond documentation. The approval was granted by a majority vote of shareholders. Aktieselskabet Schouw & Co. (CPSE:SCHO) is a Danish industrial group with holdings across several sectors, and BioMar has been one of its key subsidiaries. The shareholder-backed decision to remove...

Most readers would already know that TORM's (CPH:TRMD A) stock increased by 9.3% over the past three months. Given that...

By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...

The market shrugged off Novo Nordisk A/S' ( CPH:NOVO B ) solid earnings report. We did some digging and believe...

Key Insights Zealand Pharma's significant retail investors ownership suggests that the key decisions are influenced by...

In early February 2026, Novo Nordisk reported full-year 2025 results showing higher annual sales and earnings, proposed a DKK 11.70 total dividend per share for 2025, authorized a DKK 15,000 million buyback, and released positive phase 3 REIMAGINE 2 data for its CagriSema combination in type 2 diabetes. At the same time, Novo Nordisk moved to protect its GLP-1 franchise by suing Hims & Hers over compounded obesity drugs and preparing new Wegovy vial formats, highlighting how intellectual...

If you are wondering whether Novozymes is priced attractively or looks fully valued right now, this article will walk through the key numbers that matter. With the share price at DKK 400.0, recent returns have been mixed, including a 4.4% gain over the last 7 days, a 5.3% decline over 30 days, a 0.8% gain year to date, a 1.8% decline over 1 year, and gains of 21.9% and 11.5% across 3 and 5 years respectively. Recent news coverage around Novozymes has mainly focused on its position as a major...

DSV (CPSE:DSV) has drawn fresh attention after releasing its full year 2025 results, along with new 2026 EBIT guidance that includes expected synergies from the Schenker integration and a proposed ordinary dividend for 2025. See our latest analysis for DSV. At a share price of DKK 1,690.0, DSV has pulled back with a 1 day share price return of 0.73% decline and a 7 day share price return of 9.91% decline, even though the 90 day share price return of 19.65% and 1 year total shareholder return...